Sastre-GarrigaJParetoDBattagliniM, et al. MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice. Nat Rev Neurol2020; 16(3): 171–182.
2.
CagolASchaedelinSBarakovicM, et al. Association of brain atrophy with disease progression independent of relapse activity in patients with relapsing multiple sclerosis. JAMA Neurol2022; 79: 682–692.
3.
ZivadinovRLeHHKeenanA, et al. A systematic literature review of the association between global brain atrophy and the Expanded Disability Status Scale score in people with multiple sclerosis. Ther Adv Neurol Disord2025; 18: 17562864241303681–17562864241303261.
4.
SormaniMPArnoldDLDe StefanoN.Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol2014; 75: 43–49.
5.
SormaniMPSchiavettiIPonzanoM, et al. Treatment effect on brain atrophy correlates with treatment effect on cognition in multiple sclerosis. Ann Neurol2023; 94(5): 925–932.
6.
CagolASchaedelinSPretzschR, et al. The effect of disease-modifying therapies on brain volume loss and disability accumulation in multiple sclerosis: A systematic review and network meta-analysis. Lancet Reg Health Eur2025; 59: 101476.
7.
ArnoldDLSprengerTBar-OrA, et al. Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS. Mult Scler2022; 28(12): 1927–1936.
8.
KochMMostertJStrijbisEM, et al. Breaking the PROMISE: Poor association between brain volume loss and clinical disability worsening over 2 years of follow-up in primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. Epub ahead of print 28 January 2026. DOI: 10.1136/jnnp-2025-337940.
9.
CapannaMSignoriASormaniMP.Is the effect of drugs in progressive MS only due to an effect on inflammation? A subgroup meta-analysis of randomised trials. Mult Scler2022; 28(11): 1744–1751.
10.
De StefanoNBattagliniMParetoD, et al. MAGNIMS recommendations for harmonization of MRI data in MS multicenter studies. NeuroImage Clin2022; 34: 102972.
11.
KaçarSvan NederpeltDRJelgerhuisJR, et al. Brain atrophy rates vary with age in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. Epub ahead of print 4 February 2026. DOI: 10.1136/jnnp-2025-337779.
12.
Van NederpeltDRBosLMattiesingRM, et al. Multiple sclerosis-specific reference curves for brain volumes to explain disease severity. Neurology2025; 104: 1–13.
